In an article published in 2019, M. Scott Harris, et al. analyse the strong decrease in recruitment rate in IBD clinical trials that occurred between 1998 and 2018.
Several causes are identified, and notably an increasing number of drugs in development, therapeutic alternatives to investigational agents, exposure to a placebo as well as trial complexities.
On the basis of this analysis, the authors suggest potential solutions to address the recruitment issue, such as extending the pool of patients and simplifying studies. Yet, they do not mention digital solutions.
Following this article, Prof. Yoram Bouhnik (Head of Gastroenterology and IBD Department, Beaujon Hospital, APHP, University Paris – Diderot) responds to Harris et al. He discusses digital tool’s contribution, and presents the results achieved with the use of CT-SCOUT™, a multi-device web application based on a unique algorithmic model to boost patient recruitment in clinical trials.
These results are based on a study conducted worldwide (6 countries, 134 centers, 644 patients) and show a quadrupled randomization rate for UC (Ulcerative Colitis) studies and a doubled one for Crohn’s Disease study in sites using CT-SCOUT™ (Bouhnik Y et al. UEGW, Barcelona, 2019).
These results are based on a study conducted worldwide (6 countries, 134 centers, 644 patients) and show a randomization rate increased by 4-fold for the UC (Ulcerative Colitis) studies and by 2-fold for the Crohn’s Disease studies in sites using CT-SCOUT™ (Bouhnik Y et al. UEGW, Barcelona, 2019).
To read full article, click on the link: